This is the authors' abstract. We don't add key points for this paper.
Neurocognitive impairment is a significant yet often underappreciated complication in individuals co-infected with human immunodeficiency virus (HIV) and sickle cell disease (SCD). This review explores the interplay between these two conditions, highlighting the mechanisms that contribute to cognitive deficits. Chronic inflammation, vascular complications, and psychosocial stressors associated with both HIV and SCD create a unique vulnerability to neurocognitive decline, impacting daily functioning and overall quality of life. The prevalence of neurocognitive impairment in this population is concerning, with studies indicating that individuals with SCD may experience increased cognitive challenges due to the compounded effects of their condition and HIV-related factors. This article synthesizes current research on the prevalence, risk factors, and potential interventions for managing neurocognitive impairment in HIV-positive sickle cell patients. By identifying the unique challenges faced by this population, we can develop targeted therapeutic strategies aimed at preserving cognitive function and enhancing the quality of life.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Obeagu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: